The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. https://allenbvdz502792.ka-blogs.com/92267222/glp-3-retatrutide-a-comparative-analysis